SEP 8·rttnews.comLow
EnGene Therapeutics Inc. Earnings At $32.50 Mln In Q3
EnGene Therapeutics Inc. (ENGN) reported Q3 earnings of $32.50 million, or $0.47 per share, down from $28.99 million, or $0.57 per share, in the same period last year.
StockNASDAQ · US · USDHealthcare · Biotechnology
$ENGN
enGene Therapeutics Inc.
Price · $ENGNvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $ENGN in the last 7 days.
Insider · 30dAll trades →
No SEC Form 4 filings for $ENGN in the last 30 days.
See all $ENGN insider activity →Top stories · $ENGNMore →
SEP 8·leaderpost.com
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
enGene Therapeutics reported Q3 2026 financial results, with $266.3M in cash and a net loss of $32.5M. The company plans to update key regulatory data, hold a pre-BLA meeting, and initiate a BLA submission for detalimogene in Q4 2026. It also announced a surfactant safety run-in clearance and a webinar on preclinical data. The company is well-capitalized to support BLA filing and precommercial readiness.
SEP 8·tradingview.com
enGene Therapeutics Inc. 3Q FY2026: Net loss $32.5M, EPS ($0.47) — 10-Q Summary
enGene Therapeutics Inc. reported a net loss of $32.5M for 3Q FY2026, an increase from $29M in the same period last year. Diluted loss per share was $0.47, an improvement from $0.57. The company had no product revenue. Clinical progress was noted in the LEGEND study, with a 54% any-time complete response rate. The company plans to submit a BLA in Q4 2026 and expects cash to last at least 12 months.
ENGN sentiment & insider activity
Recent ENGN coverage spans earnings, financial news and corporate actions.
What's driving ENGN
Small profit increase may slightly improve sentiment but limited market impact.
The earnings release shows higher operating expenses and a modest net loss, but strong cash reserves and progress toward FDA submission may support near‑term stability.
Loss widening and no revenue offset positive trial data; upcoming BLA could drive upside if successful.
The earnings release provides fresh guidance on cash runway and upcoming BLA filing, likely influencing short‑term price volatility.
The article is a consensus price-target cut with unchanged “Hold” rating, implying limited near-term catalyst from analysts alone.
AlphAI scores every news story that mentions ENGN with an AI model for sentiment and relevance, and aggregates insider trades from enGene Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $ENGN
Score
EnGene Therapeutics Inc. Earnings At $32.50 Mln In Q3
EnGene Therapeutics Inc. (ENGN) reported Q3 earnings of $32.50 million, or $0.47 per share, down from $28.99 million, or $0.57 per share, in the same period last year.
1 min read
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
enGene Therapeutics reported Q3 2026 financial results, with $266.3M in cash and a net loss of $32.5M. The company plans to update key regulatory data, hold a pre-BLA meeting, and initiate a BLA submission for detalimogene in Q4 2026. It also announced a surfactant safety run-in clearance and a webinar on preclinical data. The company is well-capitalized to support BLA filing and precommercial readiness.
3 min read
enGene Therapeutics Inc. 3Q FY2026: Net loss $32.5M, EPS ($0.47) — 10-Q Summary
enGene Therapeutics Inc. reported a net loss of $32.5M for 3Q FY2026, an increase from $29M in the same period last year. Diluted loss per share was $0.47, an improvement from $0.57. The company had no product revenue. Clinical progress was noted in the LEGEND study, with a 54% any-time complete response rate. The company plans to submit a BLA in Q4 2026 and expects cash to last at least 12 months.
1 min readenGene Therapeutics Inc. (ENGN): Results of Operations and Financial Condition
enGene Therapeutics Inc. (ENGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 enGene Reports Third Quarter 2026 Financial Results and Provides Business Update Data update on key regulatory endpoints, complete response (CR) at any time and maturing durability, as well as landmark CR rates from LEGEND's pivotal cohort planned for 4Q 2026 Pre-Bio
2 min readenGene Therapeutics Inc. Stock 12‑Month Price Target Cut to $3.43, Implies 102% Upside
Analyst estimates for enGene Therapeutics Inc. show its average 12-month price target was cut from $3.50 to $3.43, with a range of $2 to $5 per share. Based on the Aug. 14 close, the target implies about 102% upside. The consensus rating remains “Hold” with 4 Buys, 5 Holds, and 1 Sell.
1 min readenGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
enGene Therapeutics (Nasdaq: ENGN) announced board changes, with Michael Heffernan becoming Chairman and Dr. Richard Glickman stepping down. The company plans a 2H 2026 FDA Pre-BLA meeting and BLA submission for detalimogene, targeting potential FDA approval in 2027. Detalimogene is in Phase 2 LEGEND for high-risk BCG-unresponsive NMIBC.
4 min readenGene Therapeutics Inc. (ENGN): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
enGene Therapeutics Inc. (ENGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001980845 00-0000000 0001980845 us-gaap:CommonStockMember 2026-07-15 2026-07-15 0001980845 2026-07-15 2026-07-15 0001980845 us-gaap:WarrantMember 2026-07-15 2026-07-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursu
3 min readWeekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera
Biotech news roundup: Spero (SPRO) and GSK won FDA approval for Utebzi (tebipenem pivoxil) for complicated UTIs; AbbVie (ABBV) expanded FDA approval of SKINVIVE by JUVÉDERM to neck lines; Cuprina (CUPR) received 510(k) clearance for MEDIFLY maggots. Neumora (NMRA) halted KOASTAL Phase 3 and plans 35% layoffs; enGene (ENGN) cuts ~50%. Biogen (BIIB) agreed to buy RayThera for up to $1B.
6 min readenGene Therapeutics Inc. (ENGN): Results of Operations and Financial Condition
enGene Therapeutics Inc. (ENGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 engn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 enGene Reports Second Quarter 2026 Financial Results and Provides Business Update 12-month complete response data from LEGEND pivotal cohort and subsequent FDA engagement planned for 2H 2026 Initiation of Biologics License Ap
6 min readenGene Therapeutics Inc. (ENGN): Submission of Matters to a Vote of Security Holders
enGene Therapeutics Inc. (ENGN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001980845 00-0000000 0001980845 us-gaap:CommonStockMember 2026-06-09 2026-06-09 0001980845 2026-06-09 2026-06-09 0001980845 us-gaap:WarrantMember 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursu
2 min read